What is the most likely cause of my H. pylori-negative mild gastritis?

Most Likely Causes of H. pylori-Negative Mild Gastritis

Your H. pylori-negative mild gastritis is most likely caused by proton pump inhibitor (PPI) use, nonsteroidal anti-inflammatory drugs (NSAIDs), or represents autoimmune gastritis—with PPI use being the most common culprit in clinical practice.

Primary Diagnostic Considerations

1. Medication-Induced Gastritis

PPI-related gastritis is the leading cause of H. pylori-negative gastritis in contemporary practice. PPIs fundamentally alter the gastric environment and can mask H. pylori infection while promoting inactive chronic gastritis 1. Research demonstrates that patients with previous PPI exposure are significantly more likely to be diagnosed with non-H. pylori gastritis (34.2% vs 71% without PPI exposure, P < 0.001) 1.

The mechanism involves:

• Suppression of H. pylori density to undetectable levels
• Shift of bacterial colonization from antrum to corpus
• Development of inactive chronic gastritis pattern 2

NSAID-induced gastritis represents the second most common medication cause, accounting for approximately 44% (8/18) of H. pylori-negative duodenal ulcers in one series 3. NSAIDs cause direct mucosal injury independent of acid secretion.

2. Autoimmune Gastritis (AIG)

This should be strongly considered, particularly if you have:

• Corpus-predominant inflammation on biopsy
• Vitamin B12 or iron deficiency 4
• Other autoimmune conditions, especially thyroid disease (present in up to one-third of AIG patients) 4
• Female gender (higher prevalence than males) 4

Key distinguishing feature: AIG causes corpus-predominant atrophic gastritis, while H. pylori typically causes antral-predominant disease initially 4.

3. False-Negative H. pylori Testing

Before accepting a true H. pylori-negative diagnosis, consider that testing may be falsely negative due to:

• Recent antibiotic use (22% of H. pylori-negative cases) 3
• Current PPI therapy suppressing bacterial density 1, 2
• Sampling error (organisms may be present only in corpus during PPI therapy) 2

Critical pitfall: In patients on profound acid suppression, H. pylori testing should be performed on combined corpus and antral specimens, not antrum alone 2.

4. Other Infectious Causes

While uncommon, consider:

• Gastrospirillum hominis infection 3
• Cytomegalovirus (in immunocompromised patients) 5
• Fungal infections (Candida in immunocompromised) 5
• Gastric tuberculosis or syphilis (rare) 5

5. Reactive Gastropathy

This includes:

• Bile reflux gastritis (chronic bile acid reflux) 4
• Focal active gastritis mimicking H. pylori infection 6

Recommended Diagnostic Algorithm

Step 1: Review medication history

• Document all PPI use (current and past 4 weeks)
• Document NSAID/aspirin use
• Document recent antibiotic exposure

Step 2: If on PPIs, consider stopping for 2 weeks and retesting for H. pylori with:

• Combined antral AND corpus biopsies 2
• Stool antigen or urea breath test (more reliable than biopsy-based tests during PPI therapy)

Step 3: Evaluate for autoimmune gastritis markers

• Check vitamin B12 and iron levels 4
• Check thyroid function and anti-thyroid antibodies 4
• Review biopsy for corpus vs. antral predominance
• Consider anti-parietal cell and anti-intrinsic factor antibodies if corpus-predominant

Step 4: If above negative, consider topographical gastric biopsies

• Sydney System protocol: 2 antral, 2 corpus, 1 incisura angularis 4
• Evaluate for intestinal metaplasia, atrophy pattern
• Special stains if other infections suspected

Clinical Significance

The distinction matters because:

• True H. pylori-negative gastritis has an 18% prevalence among all gastritis cases 7
• Patients with H. pylori-negative gastritis show higher cumulative incidence of gastric erosions and ulcers compared to those without gastritis 7
• The progression risk and gastric cancer potential remain unclear for H. pylori-negative gastritis with atrophy/metaplasia 7
• Autoimmune gastritis requires surveillance for type 1 gastric neuroendocrine tumors every 1-2 years 4

Bottom line: Stop PPIs if possible and retest for H. pylori with proper sampling technique. If truly negative, evaluate for autoimmune gastritis with B12/iron levels and thyroid screening. The natural history of H. pylori-negative gastritis with atrophy requires endoscopic surveillance similar to H. pylori-positive disease 8.